Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 7Triple Negative Breast Neoplasms 2Solid Tumor 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Advanced Solid Tumors 2Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer 1Fallopian Tube Neoplasms 1Advanced Solid Tumor 1Advanced Pancreatic Cancer 1Advanced Cancer 1

Interventions

Gemcitabine 4Injections 2toripalimab 1penpulimab 1pegylated granulocyte colony-stimulating factor 1irinotecan sucrosofate 1fluzoparib 1cabiralizumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1IMM-101 1Fluorouracil 1Docetaxel 1Albumin-Bound Paclitaxel 1ADI PEG20 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Pancreatic Cancer × fluzoparib × Clear all
NCT04228601 2024-08-16

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Completed
39 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡